In those patients with previously known T2DM who were admitted to hospital due to COVID-19 and required treatment with CS, 88.4% of the participants supported the option of maintaining the treatment with DPP-4i; the maintenance of metformin was supported by 18.8% and of GLP-1 RA by 19.6%. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.